Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

Summary

Propanc Biopharma positions its PRP drug as a complementary treatment to RAS inhibitors from Revolution Medicines and Erasca, suggesting potential to enhance remission duration in RAS-driven cancers.